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were prepared in a eukaryotic expression vector and expressed in cultured cells by tran- 
sient transfection, in the presence or absence of actinomycin D. 
Results: No mutations were identified in the transthyretin gene. A C to T substitution of 
nucleotide 635 of desrnin, resulting in the replacement of alanine 212 by valine (A212V) 
was identified in one family with isolated RCM. Expression of the wild type and mutant 
proteins in cultured myocytes showed no difference in the desmin'filamentous network. 
However, exposure of these cells to actinomycin D resulted in increased filament disar- 
ray and cell death in cells expressing A212V desmin. 
Conclusions: Here we describe a novel mutation in the deamin gene in a family with 
RCM The increased susceptibility of mycoytes expressing this mutation to actinomycin- 
induced cell death suggest a possible role of apoptosis in the pathologic events leading 
to RCM. 
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827-1 Does the Evidence Support the Verdict of High Profile 
Clinical Trials? A Conventional Versus Bayesian 
Perspective 
Saniav Kaul. Matthew J. Price, Sdram Padmanabhan, Vladimir Rukshin, George A. 
Diamond, Cedars Sinai Medical Center, Los Angeles, Cafifornia, UCLA School of 
Medicine, Los Angeles, Califomia. 
Background: Conventional significance tests frequently characterize clinically negligible 
differences as being 'statistically signiticant'~ Objective: To perform a Bayesian analysis 
of clinical trials and compare it with the conventional two-sided p value. Methods: Seven 
high profile trials (those having a major impact on CAD treatment) reported in the last 5 
years were identified for analysis. Results are expressed in odds ratio (OR) and associ- 
ated 95% confidence interval (CI), two-sided p value (using a chi square test), number 
needed to treat (NNT) to avoid 1 event (the inverse of the absolute risk reduction), prob- 
ability of benefit (pb) based on Bayesian analysis, and adjusted NNT (NNT/pb). Results: 
The results of the 2 analyses were discordant (p<0.05 and Pb<95%) in 5 and concordant 
(p<0.05 and Pb>95%) in 2 out of 7 trials. The probability of benefit in the discordant trials 
was low ranging from 7% for clopidogrel in CAPRIE to 30% for carvedilol in CAPRICORN 
despite statistically significant odds ratios and p values. The corresponding adjusted 
NNT values increased from a range of 29-115 to 94-3833. Conclusions: The conven- 
tional p value threshold is too liberal and does not correspond with Bayesian threshold of 
>95% probability. Investigators should rely on Bayesian analyses to safeguard against 
such errors leading to inappropriate claims. Alternatively, a more stringent conventional p 
value threshold, e.~]., <0.01 to <0.001 should be chosen. 0 
Trial N Endpoint OR (95% p NNT pb Adjusted 
CI) value NNT 10 
CAPRIE (CIopidogrel in 19413 Death, MI or 0.91 0.047 115 0.07 3833 16 
Vascular disease) stroke @ 1-3y (0.83,1.00) 20 
EP;STENT(Abciximabin 1603 Death @ ly 0.42 0.037 75 0.12 625 25 
Coronary Stenting) (0.18,0.97) 
3O 
ESSENCE + TIMI-11B 7081 Death or MI @ 0.79 0.016 75 0.20 375 
(Enoxapadn in Acute 14d (0.69,0.90) 35 
Coronary Syndrome 40 
MIRACL (Atorvastatinin 3086 Death, MI or 0.83 0.048 39 0.16 218 45 Acute Coronary Syndrome) ischemia @ 4m (0.68,1.00) 
CAPRICORN (Carvedilolin 1959 Death @ 1.3y 0.74 0.026 29 0.31 94 50 
Post-MI LV Dysfunction) (0.57,0.97) 
HOPE (Ramipril in 9297 Death, MI or 0.75 <0.001 27 >0.99 27 
Seccnary Prevention of stroke @ 5y (0.68,0.84) 
CVD) 
Lyon Diet Heart Study 423 Death or MI @ 0.25 <0.001 7 >0.99 7 
(Mediterranean Diet for 46m (0.13,0.47) 
Secondary Prevention) 
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827-2 Do Glycoproteln 2B3A Inhibitore Reduce Morta l i ty?  A 
Bayes ian  Meta-Ana lys ls  
Saniav Kaul, Matthew J. Price, Briram Padmanabhan, Vladimir Rukshin, George A. 
Diamond, Cedars Sinai Medical Center, Los Angeles, California, UCLA School of 
Medicine, Los Angeles, California. 
Background: Although nearly 50000 patients have been enrolled in clinical trials of gly- 
coprotein 2b3a inhibitors (GPIs), the issue of their effect on cardiac mortality remains 
controversial, in part, because conventional tests of statistical significance are unreliable 
when applied to such large samples. Oblectlve: To perform a Bayesian meta-analysis of 
the effect of GPIs on total mortality, and compare the resultant probability of benefit with 
the conventional p value. Methods: A total of 20 randomized trials involving 48584 
patients were identified for analysis at 30 d and 5 trials involving 10959 patients for anal- 
ysis at 1 year. Pooled trial results are expressed in terms of the odds ratio (OR) and 
associated 95% confidence interval (CI), the two-sided p value (using a chi square test), 
the probability of benefit (10b) based on Bayesian analysis, and number needed to treat 
(NNT) to avoid 1 mortality (the inverse of the absolute risk reduction). Results: At 30 
days, there were 672 deaths among 27073 GPI and 590 deaths among 21511 placebo 
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patients [OR = 0.90 (0.81, 1.01), p = 0.08, Pb = 0.02, NNT = 384]. At 1 year, there were 
251 deaths among 6729 GPI and 183 deaths among 4230 placebo patients [OR = 0.86 
(0.71, 1.04), p = 0.12, Pb = 0.03, NNT = 168]. Thus, the probability that GPI therapy 
reduced total mortality was very low (2% at 30 days and 3% at 1 year) despite odds 
ratios and p values that tended toward statistical significance. Four tdals of abciximab 
were analyzed separately (EPIC, EPILOG, EPISTENT, CADILLAC). At 1 year, there 
were 127 deaths among 5205 abciximab and 118 deaths among 3472 placebo patients 
[OR = 0.72 (0.56, 0.93), p = 0.01, Pb = 0.19, NNT = 108]. The best conventional estimate 
was a 0.93% absolute reduction in mortality with abciximab among 8677 patients. How- 
ever, there was only a 19% probability that abciximab was superior to placebo despite 
conventional statistical significance. Conclusion: The widespread belief that GPIs, spe- 
cifically abciximab, confer a significant mortality benefit is directly controverted by this 
Bayesian meta-analysis. Future large-scale clinical trials should incorporate the Baye- 
sian approach in their design and analysis in order to minimize the potential for such 
errors. 
2:30 p.m. 
827-3 Cost -E f fect iveness  of Prophylactic Amiodarone 
Therapy for the Prevention of Atrial Fibrillation in 
Patients Undergoing Cardiac Surgery Varies by 
Underlying Risk and "l~pe of Surgery: Results for 
CABG, Valve Replacement, and Combined CABG and 
Valve Replacement 
Elizabeth M. Mahonev, Jovonne K. Williams, Emir Veledar, Trevor D. Thompson, William 
S. Weintraub, Emory University School of Medicine, Atlanta, Georgia. 
Background. The selection of patients (Lots) for whom prophylactic amiodarone therapy to 
prevent atrial fibrillation (AF) following cardiac surgery is cost-effective (CE) is difficult. 
This study adds to previous efforts by separately examining the risk and added costs of 
AF in CABG, valve replacement (VR) and combined CABG and VR (CABG+VR) pts. 
Methods. Outcomes and costs for 8709 CABG, 1217 VR and 624 CABG+VR pts at 
Emory University Hospitals from 1/94-6/99 were used to examine the CE of targeted ami- 
odarone therapy for each of the three types of surgical patients. Logistic regression was 
used to develop models for the prediction of AF and linear regression was used to predict 
hospital costs, including the additional costs attributed to AF. Predicted probabilities from 
the logistic models were used as the index from which to identify patient subsets to be 
targeted for therapy. Marginal CE of targeting therapy to subsets at incrementally lower 
levels of risk was evaluated. CE was evaluated as cost/episode of AF averted. Effective- 
ness of amiodarone was assumed to be 26% (ARCH trial) and cost $973 (7 amps/day for 
2 days at $69.50/amp). 
Results. AF rates were 17.7% for CABG, 24.6% for VR and 33.8% for CABG+VR. 
Treatment CABG: CABG: VR: VR: CABG+VR: CABG+VR: 
Threshold: % treated marginal % treated marginal % treated marginal 
Probability of AF cost/AF cost/AF cost/AF 
averted averted averted 
100 $55,854 100 $43,011 100 $39,698 
77.7 $34,087 91.7 $27,061 99.0 $22,009 
55.5 $25,224 78.0 $18,658 95.4 $14,325 
36.4 $20,540 60.6 $13,687 88.6 $9,903 
21.3 $17,479 44.6 $10,603 76.0 $7,178 
10.6 $15,406 32.2 $8,626 63.8 $4,947 
4.2 $13,864 19.1  $7,179 42.6 $3,430 
1.5 $12,696 9.1 $5,990 27.9 $2,346 
0.5 $11,789 3.5 • $5,089 14.4 $1,423 
0.1 1.1 -- 9.3 -- 
Conclusions: Using $5000 as an acceptable cost/AF averted, prophylactic amiodarone 
use in CABG pts is not cost-effective. Therapy would be recommended for a small frac- 
tion of VR pts who have a predicted risk of AF>45% and roughly 2/3 of CABG+VR pts 
who have a predicted risk of AF>30%. Nomograms can help identify these pts. 
2:45 p.m. 
827-4 The Intermountaln Risk Model :  Predict ing Morta l i ty  by 
Traditional and Novel Risk Factors Among Patients With 
Sign i f icant  Coronary  Disease 
Beniamin D. Home, Joseph B. Muhlestain, Chloe A. Allen Maycock, John F. Carlquist, 
Donald L. Lappe', Robert R. Pearson, Dale G. Renlund, Jeffrey L. Anderson, LDS 
Hospital, Salt Lake City, Utah, University of Utah, Salt Lake Ci~ Utah. 
Background: Although treatment guidelines exist for guiding the therapy of patients with 
diagnosed coronary artery disease (CAD), they are largely based on risk models that 
predict CAD onset, not mortality after disease has developed. No mortality risk model 
has been created with data from the general CAD patient population. This study evalu- 
ated predictive risk models for mortality among patients with significant, angiographically- 
defined CAD. 
Methods: The catheterization registry of the Intermountain Heart Collaborative Study 
provided a cohort of 2,585 patients with significant, angiographically-proven CAD (>_1 
lesion of ->70% stenosis). At angiography, 16 traditional and 3 novel (C-reactive protein 
[CRP], cytomegalovirus [CMV], homocysteine [HCY]) risk factors were measured. 
Patients were followed for 2.4±1.6 years (maximum: 5.8 years) to determine the inci- 
dence of mortality. 
Results: Average age was 65±11 years, 76% were male, and 250 (9.7%) died. Prsdic- 
